NCT04858997View on ClinicalTrials.gov

Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients

PHASE2UnknownINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 22, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

June 30, 2023

Conditions
Breast Neoplasms
Interventions
DRUG

Palbociclib

Palbociclib,125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

DRUG

AI

AI, orally once daily (continuously)

Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Zhejiang Cancer Hospital

OTHER

NCT04858997 - Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients | Biotech Hunter | Biotech Hunter